IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding IN8BIO, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 15 | 17 | +2 |
| Shares | 2.36M | 1.20M | −1.16M (−49.0%) |
| Value | $5.50M | $2.42M | −$3.08M (−56.0%) |
New holders (6)
Institutions that held IN8BIO, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 52,347 | $105.0K | 0.00% |
| Precept Management LLC | 50,000 | $101.0K | 0.80% |
| Warberg Asset Management LLC | 15,000 | $30.0K | 0.01% |
| HighTower Advisors, LLC | 14,164 | $28.0K | 0.00% |
| United Asset Strategies, Inc. | 14,000 | $28.0K | 0.00% |
| Royal Bank of Canada | 140 | $0 | 0.00% |
Sold out (4)
Institutions that held IN8BIO, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Capital World Investors | 774,742 | $1.88M |
| B. Riley Financial, Inc. | 257,513 | $582.0K |
| Nantahala Capital Management, LLC | 148,801 | $359.0K |
| Two Sigma Securities, LLC | 29,858 | $67.0K |